Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs.

ABSTRACT:

Background

Insurers manage the cost of specialty medicines via rebates, however it is unclear if the savings are passed on to patients, and whether reducing rebates may lead to changes in patient out-of-pocket (OOP) costs and medication adherence. This study examined two drug classes to understand the impact of reducing list prices to net prices, via lower-priced national drug codes (NDCs) or authorized generics, on patient OOP costs and adherence.

Methods

This retrospective analysis assessed IQVIA PharMetrics ® Plus adjudicated medical and pharmacy claims for commercially insured patients. Patient OOP costs per prescription and payer drug costs were assessed for evolocumab or alirocumab (proprotein convertase subtilisin/kexin type 9 inhibitors [PCSK9is]) or velpatasvir/sofo

SUBMITTER: Wong WB 

PROVIDER: S-EPMC9851557 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature